Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy

AIM: This study assessed the efficacy and safety of upadacitinib (UPA), in combination with conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), in Chinese, Brazilian, and South Korean patients with active rheumatoid arthritis (RA) and an inadequate response (IR) to csDMARDs. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xiaofeng, Zhao, Dongbao, Radominski, Sebastiao C., Keiserman, Mauro, Lee, Chang K., Meerwein, Sebastian, Enejosa, Jeffrey, Sui, Yunxia, Mohamed, Mohamed‐Eslam F., Park, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299142/
https://www.ncbi.nlm.nih.gov/pubmed/34779576
http://dx.doi.org/10.1111/1756-185X.14235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299142/
https://www.ncbi.nlm.nih.gov/pubmed/34779576
http://dx.doi.org/10.1111/1756-185X.14235

Ejemplares similares